Novel first-in-class drug candidates for the treatment of neurodegenerative diseases

Bionure is a clinical stage R&D company developing first-in-class small molecule drug candidates for the treatment of neurodegenerative diseases, that benefit from treatment options with limited efficacy.


Our lead candidate, BN201, has shown compelling evidence of neuroprotective and remyelinating activity in several animal models and is completing a Phase 1 clinical study.


The next step of development will be to initiate an efficacy proof-of-concept Phase 2 clinical trial with BN201 in patients suffering from neurodegenerative diseases with high unmet needs, such as acute optic neuritis, a rare ophthalmological disease for which BN201 has been granted orphan drug status both in Europe and in the USA, and multiple sclerosis.


To guide our development efforts, we have built an extraordinary team of experts in neuro-ophthalmology and neuro-inflammation, committed and passionate about bringing meaningful therapies to society with the aim of changing the life of people enduring disabilities related to neurodegeneration.


The company was founded in 2009 as an academic spin-off from the Hospital Clinic of Barcelona (Spain) and further developed into a small R&D drug company. In 2018 Bionure strengthened its initial and solid shareholder base of business angels and family offices to welcome a first Venture Capital investor, Alta Life Sciences, a solid pillar for future syndication of professional investors to support both corporate and drug development activities.

Bionure has participated in the following projects. These projects have received funding from the Ministry of Science and Innovation, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011. They have been co-financed by the European Regional Development Fund (ERDF).


Bionure has received non-dilutive funding support from the following local, national and european governments:


Nuevas aproximaciones terapéuticas para la Esclerosis Múltiple y la Esclerosis Lateral Amiotrófica: efectos modificadores de la enfermedad y neuroprotección

(expediente IPT-010000-2010-035) liderado por Advanced in Vitro Cell Technologies SA y en el que también participan Neurotec Pharma SL y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.

STOP-ELA: Aproximación multi-tecnológica para el desarrollo de nuevas terapias y sistemas avanzados de administración farmacológica para la Esclerosis Lateral Amiotrófica

(expediente IPT-2011-1091-900000) liderado por Neurotec Pharma SL y en el que también participan Advanced in Vitro Cell Technologies SA, Palo Biofarma SL, Natac Biotech SL, Universidad de Zaragoza y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer

Desarrollo de terapias neuroprotectoras para Esclerosis Múltiple

(expediente IPT-2011-1312-900000) liderado por Digna Biotech SL, y en que también participan la Fundación Privada Institut d’Investigació Biomèdica de Bellvitge y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.

Our team

Top-tier professionals and experts working towards a common goal

Dr. Laurent Nguyen
Chief Executive Officer
Mar Massó
Managing Director
Pablo Villoslada
Craig Smith
Stéphane Paris
Scientific R&D Project Manager
Julián Peña
Administration & Finance
José Luis Fabregas
CMC advisor
Lindsay Donald
Toxicology advisor
Pablo Villoslada
Co-founder. MD and PhD; Director of Neuroimmunology at University Hospital Clínic of Barcelona.
Albert G. Zamora
Co-founder. MBA.
guy nohra
Guy P. Nohra
Partner at Alta Life Sciences (Chair)
Montserrat Vendrell
Partner at Alta Life Sciences (Vice Chair)
Salut Monràs
CEO Valrà Finances
Paul Frohna
Chief Medical Officer at Bioniz Therapeutics, Inc.
Rahiv Mahadevan
Managing Director at Precision for Medicine
Joaquim Trias
PhD; President at JPTS; Co-founder of Vicuron, Peninsula, Anthera, Tetraphase and Microcide
Larry Steinman
MD; Professor of Neurology at Stanford University; Co-founder of Atreca, Nuon Therapeutics, Neurocrine Biosciences and Bayhill Therapeutics
Stephen Hauser
MD; Chairman and Professor of Neurology at UCSF
Amir Bar-Or
MD; Director of the Center for Neuroinflammation and Neurotherapies: Chief of the Multiple Sclerosis Center at the University of Pennsylvania Perelman School of Medicine (Philadelphia, USA)
Ari Green
MD; Clinical Director of the UCSF MS Center; Director of the UCSF Neurodiagnostics Center
Craig Smith
MD; Advisor of the Bill and Melinda Gates Foundation


We look forward to pursuing partnership opportunities with industry leaders.


The National MS Society mobilizes people and resources to drive research for a cure and to address the challenges of everyone affected by MS. The National MS Society is committed to achieving a world free of MS. Bionure has been funded by the National MS Society through Fast Forward program.


Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS.


Reig Jofre is a pharmaceutical company focused on the research, development, manufacture and marketing of medicines and nutritional supplements, as well as on specialized manufacturing for third parties. Bionure collaborates with Reig Jofre in the formulation of its lead candidate.


Fundació GAEM is a non-profit organization supporting innovation to bring new therapeutics for multiple sclerosis patients.


The Myelin Repair Foundation (MRF) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis. Under the partnership with the MRF, Bionure’s BN201 has been shown to promote myelin repair.